Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma.
Adenocarcinoma
/ pathology
Adenocarcinoma, Mucinous
/ drug therapy
Adenocarcinoma, Papillary
/ pathology
Carcinoma, Pancreatic Ductal
/ drug therapy
Chemotherapy, Adjuvant
Humans
Neoplasm Invasiveness
Pancreatic Intraductal Neoplasms
Pancreatic Neoplasms
/ drug therapy
Retrospective Studies
Pancreatic Neoplasms
Adjuvant chemotherapy
invasive IPMC
lymph node metastasis
poorly differentiated adenocarcinoma
tubular type
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
08
01
2022
revised:
04
04
2022
accepted:
05
04
2022
entrez:
30
4
2022
pubmed:
1
5
2022
medline:
4
5
2022
Statut:
ppublish
Résumé
This study evaluated the efficacy of adjuvant chemotherapy (AC) for intraductal papillary mucinous carcinoma (IPMC). We retrospectively analyzed patients who underwent pancreatectomy for invasive IPMC from January 2007 to June 2020. We evaluated outcomes of AC in the entire cohort and in patients with known prognostic factors. A total of 51 patients with invasive IPMC underwent surgery, of which 35 received AC. In the entire cohort, there was no significant difference in median overall survival (OS) between the AC and surgery alone (SA) group [hazard ratio (HR)=0.54; p=0.232]. For patients with poorly differentiated adenocarcinoma, median OS was significantly longer in the AC group (HR=0.27; p=0.022). For patients with lymph node metastasis, median OS was significantly higher in the AC group (HR=0.07; p<0.001). AC may be effective for selected invasive IPMC patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
This study evaluated the efficacy of adjuvant chemotherapy (AC) for intraductal papillary mucinous carcinoma (IPMC).
PATIENTS AND METHODS
METHODS
We retrospectively analyzed patients who underwent pancreatectomy for invasive IPMC from January 2007 to June 2020. We evaluated outcomes of AC in the entire cohort and in patients with known prognostic factors.
RESULTS
RESULTS
A total of 51 patients with invasive IPMC underwent surgery, of which 35 received AC. In the entire cohort, there was no significant difference in median overall survival (OS) between the AC and surgery alone (SA) group [hazard ratio (HR)=0.54; p=0.232]. For patients with poorly differentiated adenocarcinoma, median OS was significantly longer in the AC group (HR=0.27; p=0.022). For patients with lymph node metastasis, median OS was significantly higher in the AC group (HR=0.07; p<0.001).
CONCLUSION
CONCLUSIONS
AC may be effective for selected invasive IPMC patients.
Identifiants
pubmed: 35489761
pii: 42/5/2645
doi: 10.21873/anticanres.15742
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2645-2655Informations de copyright
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.